Laurus Labs Invests ₹49 Crore in KRKA Pharma Rights Issue
Laurus Labs Limited has announced an update regarding its proposed equity investment in KRKA Pharma Private Limited, a joint venture of the company. In continuation of their previous intimation dated ...
Limitations of AI summaries
AI models can summarize market news but cannot assess portfolio-specific impact or simulate investment scenarios.
Platforms like Prysm provide stock-level and portfolio-level analysis.
Why is Laurus Labs Limited in the news today?
Laurus Labs Limited (LAURUSLABS) is in the news due to the announcement details a routine investment in a joint venture through a rights issue, which is a standard corporate action and does not inherently suggest a positive or negative shift in the company's performance or outlook.
AI-Powered Summary
Market Context
Top Queries
More News
Explore Prysm Tools
Related Stories
Laurus Labs Invests ₹49 Crore in KRKA Pharma Rights Issue
December 23, 2025, 10:43 AM
Top Queries to Ask About Laurus Labs Limited
Laurus Labs Limited has announced an update regarding its proposed equity investment in KRKA Pharma Private Limited, a joint venture of the company. In continuation of their previous intimation dated July 25, 2025, Laurus Labs has invested ₹490,000,000 (Indian Rupees Four Hundred and Ninety Million only) in KRKA Pharma.
This investment was made through a rights issue, through which Laurus Labs acquired 49,000,000 equity shares of KRKA Pharma, each with a face value of ₹10, aggregating to the total investment amount of ₹490,000,000.
This disclosure is made as per Regulation 30(7) of SEBI (LODR) Regulations, 2015.
See What Deep Dive Gives You — in Seconds
“what happens when you click
Deep Dive “
“what happens when you click Deep Dive “
Instant AI Summary - “Get clean, noise-free earnings breakdowns.”
PDF Insights - “Download detailed, AI-generated reports.”
Metrics Explained -“Key ratios & trends explained in simple language.”
Want to know if this news pushes your stock up or down?
Just tap
